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Abstract
Background: This study aimed to investigate squamous cellular carcinoma antigen (SCCA) in
serum and in tumoral and paired peritumoral tissues. We studied 27 patients with liver cirrhosis
(LC) and 55 with HCC: 20 with a single nodule < 3 cm (s-HCC) and 35 with a single nodule > 3
cm or multifocal (l-HCC).
Methods:  Serum SCCA was measured by the ELISA kit, and in frozen tissues by
immunohistochemistry, quantified with appropriate imaging analysis software and expressed in
square microns. Continuous variables are reported as means and 95% confidence intervals.
Comparisons between independent groups were performed with a generalized linear model and
Tukey grouping. Pearson's correlation coefficients were determined to evaluate relations between
markers. Qualitative variables were summarized as count and percentage. Statistical significance
was set at p-value < 0.05.
Results: Serum SCCA values in LC patients were 0.41 (0.31–0.55) ng/ml and statistically different
from both HCC groups: 1.6 (1.0–2.6) ng/ml in s-HCC, 2.2 (1.28–2.74) ng/ml in l-HCC. SCCA in
hepatic tissue was 263.8 (176.6–394.01) μm2 in LC patients, statistically different from values in s-
HCC: 1163.2 (863.6–1566.8) μm2 and l-HCC: 625.8 (534.5–732.6). All pairwise comparisons
between groups yielded statistically significant differences. Tumoral SCCA resulted linearly related
with nodule size, showing a statistically significant inverse relation between the two variables (b =
-0.099, p = 0.024).
Conclusion: There was no statistically significant correlation between tissue and serum levels of
SCCA. The significantly stronger expression of SCCA in smaller compared to larger HCC could
be important for early HCC detection. However, the increased expression in peritumoral tissue
could affect the significance of serological detection.
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Background
Early recognition of the onset of hepatocellular carcinoma
(HCC) would help to select more effective therapies for
patients, leading to a better prognosis and life span. For
this reason surveillance programs were strongly recom-
mended at a Consensus Conference held in Barcelona [1].
Alphafetoprotein (AFP), the only marker commonly used
in clinical practise, displays poor sensitivity and a high
specificity only for values higher than 400 IU/ml. How-
ever, because AFP concentrations are directly correlated
with tumor size, the reliability of such a marker appears
inadequate for early recognition of HCC [2]. This has
prompted a high number of studies conducted to validate
different new biomarkers, but very little has yet been
reported about biomarkers helping to achieve an early
detection of HCC [3]. All the proposed biomarkers failed
to discriminate between liver cirrhosis (LC) and HCC in a
satisfactory manner, in terms of diagnostic accuracy,
reproducibility of the results, or technical issues related to
the biomarker detection method [4]. For this reason, the
simultaneous use of different tests seems to offer a prom-
ising approach that warrants further investigation [5].
Squamous cellular carcinoma antigen (SCCA), is a mem-
ber of the high molecular weight family of serine protease
inhibitors named serpins [6]. Two highly homologous
isoforms have been reported to be expressed in HCC tis-
sues at protein and translational levels [7]. SCCA has also
been reported to be overexpressed in tumoral compared
to paired peritumoral tissue of HCC, suggesting a role as a
potential marker for histological detection of HCC [8].
Recently, SCCA has been investigated in regenerative and
dysplastic nodules of HCC tissue. Interestingly, results
show that SCCA was poorly expressed in regenerative tis-
sue but strongly increased in dysplastic nodules, suggest-
ing a role as a potential marker for early detection of HCC
[9].
Aim of this study is to investigate the tissue expression of
SCCA in patients with different characteristics of HCC,
namely small and large or multifocal nodules.
Results
SCCA was quantified in matching sera and tissues of 82
patients, 27 LC and 55 HCC. In these latter patients tissue
expression of SCCA was investigated in neoplastic and
paired peritumoral tissue. Patients were stratified accord-
ing to nodule size. The mean (95%CI) size of the HCC
lesion was 4.07 ± 2.08 cm; 36.4% (20/55) patients had a
single nodule smaller or equal to 3 cm (s-HCC) and
63.6% (35/55) a nodule larger than 3 cm or multifocal (l-
HCC). A statistically significant difference (p = 0.01) was
observed in the percentage of Child-Pugh stage A among
s-HCC (55%), l-HCC (82%) and LC (88%). The most fre-
quent etiology was HCV alone or with HBV, with no sig-
nificant difference among groups (p = 0.108): 65% (15/
20) in s-HCC, 71.4% (25/35) l-HCC and 92.6% (25/27)
for LC patients (Table 1).
Table 1: Characteristics of the patients
Single nodule ≤ 3 cm Single nodule > 3 cm Total HCC LC
Sex M 16 28 44 17
F4 7 1 1 1 0
Age 65 (10.15) 65 (10. 2) 65 (10.1)
Size 2..4 (0.5) 5 (2) 4 (2.1)
CLIP 0 7 15 22
11 0 1 7 2 7
23 3 6
27
CHILD A 11 29 40 24
B9 6 1 5 3
Etiology Alcohol or Other 1 2 3 1
HBV 3 8 11 1
HBV+Alcohol 1 1
Total HBV 4 8 12 1
HCV alone 13 23 36 24
HCV+HBV 1 2 3
HCV+Alcohol or other 1 1 1
Total HCV 15 25 40 25Molecular Cancer 2009, 8:29 http://www.molecular-cancer.com/content/8/1/29
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SCCA was detected by immunohistochemistry in all the
patients, although with some differences, in both tumoral
and peritumoral tissues of small and large HCC (Figure
1A). In particular, the mean (95% CI) expression in neo-
plastic tissue was 1163.2 (863.6–1566.8) μm2 in s-HCC
and 625.8 (534.5–732.6) μm2 in l-HCC. There was a sta-
tistically significant difference among the groups (F =
17.45, p = 0.002) and Tukey grouping showed a signifi-
cant difference (p < 0.05) between s-HCC vs l-HCC (Fig-
ure 1B). To further investigate the tissue expression of
SCCA, paired peritumoral tissues were analyzed as well as
LC samples used as proper control. The mean (95% CI) of
SCCA tissue expression was 263.8 (176.6–394.01) μm2 in
s-HCC peritumoral tissue, 345.49 (263,98 – 452,16) μm2
in l-HCC and 232.63 (163.3–331.38) μm2 in LC, Figure 2.
The model did not result statistically significant (F = 1.84,
p = 0.16). In conclusion, SCCA was more strongly
expressed in the neoplastic tissue of smaller compared to
larger HCC. In addition, it is noteworthy that the ratio
between tumoral and peritumoral SCCA shows a trend
ranging from 4.4 in s-HCC to 1.8 of l-HCC.
In the same patients, we measured the serum concentra-
tions of SCCA. As reported in Figure 3, concentrations
were 1.6 (1.02–2.6) ng/ml in s-HCC, 2.2 (1.28–2.74) ng/
ml in l-HCC, 0.41 (0.31–0.55) ng/ml in LC patients (Fig-
ure 3). The model resulted statistically significant (F =
20.81, p < 0.0001), and Tukey grouping displayed a sig-
nificant difference (p < 0.05) between each HCC group
and LC. In conclusion, serum SCCA levels were similar in
the different HCC groups, but statistically different in the
LC group.
The underlying liver disease does not seem to affect SCCA
tissue expression levels among patients with different
Child-Pugh stages (p = 0.5) as shown by the generalized
linear model, while the only significant factor remains the
diagnosis of HCC as compared to LC (p = 0.049).
The regression model with dependent peritumoral SCCA
shows that in the subgroup of single nodule HCC, nodule
size was not statistically significant as a means of predict-
ing peritumoral SCCA (b = 0.064; F = 1.55; p = 0.219),
whereas it was a statistically significant predictor of
tumoral SCCA (b = -0.099; F = 5.47; p = 0.024; R2 =
0.117).
Linear regression between serum SCCA and nodule size
did not show a statistically significant relation between
these two variables (b = 0.023; F = 0.14; p = 0.71; R2 =
0.003).
In conclusion, tumoral SCCA depends on nodule size,
and there was an inverse trend between nodule size and
higher SCCA values. Peritumoral and serum SCCA,
instead, do not show any relation with tumor size.
The area under the ROC curve for serum SCCA was 0.897
(CI95% 0.81–0.953), with a suggested cut-off value of 1.1
ng/ml, showing 72.7% sensitivity, 100% specificity and a
72.7%Youden index. Assessing only s-HCC and LC
patients, an analogous accuracy of serum SCCA was
obtained: AUC 0.873 (CI95% 0.743–0.952), cut-off 1.1
ng/ml, with 70% sensitivity, 100% specificity and 70%
Youden index.
However, in HCC no statistically significant correlation
was observed between SCCA levels present in the tumoral
and/or peritumoral tissue and in the serum (Table 2).
Pearson's correlation coefficient resulted statistically sig-
nificant only to evaluate relations between serum levels vs
cirrhotic liver tissue expression of SCCA in LC patients:
0.39 (p = 0.04). In other words, the higher the tissue val-
ues the higher the serum values, but only in LC patients.
Finally, serum SCCA values could be expressed as a func-
tion of tumoral or peritumoral values of this marker, so a
regression analysis was performed; results are shown in
Figure 4. The models evaluated did not result statistically
significant except in LC patients (F = 5.02, p = 0.034). In
this group the slope resulted 0.33 (p = 0.034), suggesting
increased SCCA serum values with stronger tissue expres-
sion. In HCC patients, neither SCCA tumoral nor peritu-
moral tissue expression resulted predictive of the serum
levels, and this finding was consistent in both groups of
patients. Furthermore, in smaller nodules we calculated
that 711 μm2 of SCCA antigen were necessary to measure
one unit in the serum, while in larger tumors only 268
μm2 were enough.
Discussion
Lately, the investigation of new biomarkers for HCC diag-
nosis has aroused great interest because they could make
it possible to select the most effective therapy for individ-
ual patients. From this viewpoint, biomarkers helping to
detect small HCC would be a great step forward. Recently,
the tissue expression of SCCA has been reported in a
higher percentage of patients with pre-neoplastic dysplas-
tic lesions than in regenerative nodules. Moreover, in the
same study SCCA was reported to be more strongly
expressed in premalignant dysplastic nodules than in
HCC [9]. In our study a similar statistically significant dif-
ference was observed, but because of the small number of
patients (5 LC vs. 20 s-HCC patients) with dysplastic cir-
rhotic nodules, no reliable conclusion can be drawn
although it seems an interesting initial observation. Con-
sistently with these data, we report herein that SCCA is
more strongly expressed in the tissue of smaller as com-Molecular Cancer 2009, 8:29 http://www.molecular-cancer.com/content/8/1/29
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Tissue expression of SCCA Figure 1
Tissue expression of SCCA. In Figure 1A, immunohistochemistry of SCCA in small and large HCC at low (A, C) and high 
(B, D) magnification. Paired peritumoral tissue at low magnification of small (E) and large (F) HCC. In A, C, E and F scale bar = 
100 μm, in B and D scale bar = 50 μm. In Figure 1B, 95% Confidence intervals of neoplastic tissue SCCA in the different HCC 
patients groups.Molecular Cancer 2009, 8:29 http://www.molecular-cancer.com/content/8/1/29
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pared to larger HCC. For the first time, therefore, a marker
that can discriminate smaller better than larger nodules is
reported, although findings of this marker also in the tis-
sue limit its immediate application to clinical practise.
Nevertheless, results in this study contain two different
messages, firstly that SCCA could be a biomarker of pre-
malignant transformation and secondly, that the irregular
behavior of this serum biomarker could be related to a dif-
ferent biological tumor status.
In particular, the decreased SCCA expression with the pro-
gression of tumor size, and the increased expression in the
peritumoral tissue of larger HCC at higher risk of further
neoplastic transformation support our first conclusion.
These results are consistent with our previous observation
[5], and are also supported by a previous report by Pon-
tisso et al. showing that in patients with LC progressing to
HCC, SCCA was consistently increased [10]. This could
explain why SCCA could be unexpectedly increased in
some LC patients. In fact, the relation between nodule size
and tumoral SCCA in our study suggests that high levels
of SCCA expression could anticipate clinical evidence of
HCC onset.
On the other hand, the lack of correlation between tissue
and serum SCCA levels is disappointing and no explana-
tion is yet forthcoming. However, the fact that SCCA is
distributed mainly in the cytosol, not associated to mem-
brane-bound vesicles, and therefore is not properly
secreted but rather released in the serum as a consequence
of cell lysis, could contribute to clarify this issue [11]. This
hypothesis is also confirmed by our previous study show-
ing SCCA expression in some cell lines but not in the con-
ditioned medium, suggesting a defective protein secretion
[8].
Moreover, it is noteworthy that the amount of serum
SCCA does not depend on its expression level in the peri-
tumoral or LC tissue. The higher ratio in smaller than
larger nodules suggests that SCCA is produced and
released at different times, likely during the earlier events
in HCC progression; this offers another possible explana-
tion of the discrepancy between SCCA serum and tissue
levels.
In conclusion, this study suggests that SCCA tissue expres-
sion could be a marker for early detection of smaller HCC
nodules, and contributes to explain why the data in serum
can be somewhat disappointing. In addition, our results
suggest that proposed biomarkers need to be carefully
investigated and clinically validated in relation to specific
95% Confidence intervals of non neoplastic peritumoral tis- sue SCCA in the different HCC patients groups Figure 2
95% Confidence intervals of non neoplastic peritu-
moral tissue SCCA in the different HCC patients 
groups.
95% Confidence intervals of serum SCCA in the different  HCC patients groups Figure 3
95% Confidence intervals of serum SCCA in the dif-
ferent HCC patients groups.
Table 2: Pearson correlation coefficient for evaluation of relation 
between markers in HCC and LC patients
Peritumoral SCCA Tumoral SCCA
s-HCC Serum SCCA 0.01 -0.08
Tumoral SCCA 0.27
l-HCC Serum SCCA 0.05 -0.13
Tumoral SCCA 0.014
LC Serum SCCA 0.39 (p = 0.04)Molecular Cancer 2009, 8:29 http://www.molecular-cancer.com/content/8/1/29
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Scatter plot of serum SCCA in tumoral and peritumoral tissue in HCC patients, and tissue SCCA in LC patients Figure 4
Scatter plot of serum SCCA in tumoral and peritumoral tissue in HCC patients, and tissue SCCA in LC 
patients. Ln = natural logarithm.Molecular Cancer 2009, 8:29 http://www.molecular-cancer.com/content/8/1/29
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biological aspects of HCC, so as to obtain more reliable
results.
Materials and methods
Tissue and serum collection
Tissue specimens of primary nodules and of the peritu-
moral area were collected from HCC patients, as well as
specimens from LC patients. All the specimens, obtained
by surgical biopsy, were fixed in 3.7% formaldehyde and
processed for routine histology, while a part of the speci-
men was immediately snap-frozen in liquid nitrogen and
stored at -80°C until use. Serum samples from the same
patients were collected before any kind of treatment, and
stored at -20°C until use.
Patients were classified as LC and HCC according to EASL
criteria, and tumor staging was determined according to
the CLIP classification [1,12]; nodule size was determined
by concordant US and CT and/or MRI scans. SCCA was
quantified in matching sera and tissues of 82 patients, 27
LC and 55 HCC. In the latter patients, tissue expression of
SCCA was investigated in both neoplastic and paired per-
itumoral tissue.
The study was performed in accordance with the Helsinki
declaration and informed written consent was obtained
from all patients before surgery or liver biopsy and before
blood sample collection
Tissue expression of SCCA
Immunohistochemistry was performed on frozen speci-
mens as previously reported [13]. SCCA was detected
using a polyclonal antibody directed against recombinant
SCCA purchased from (Hepa-Ab, Xeptagen, Italy) and fol-
lowing the manufacturer's instructions.
The expression of SCCA was measured as μm2 of staining
by an appropriate software system (Lucia, Nikon, Corp),
already validated in several of our previous reports.
Briefly, expression of the SCCA antigen was measured in
each section as the total stained area, calculated as the
mean of ten randomly chosen microscopic fields. Figures
1 and 2 show the mean and standard deviation among all
those calculated. To normalize the quantification of the
staining, a negative control (a section incubated without
the primary antibody) was included in each experiment,
so that the sensitivity of the software was calibrated on the
background staining.
Serum determination of SCCA
Serum determination of the SCCA antigen was carried out
using an ELISA kit purchased from Xeptagen (Xeptagen,
Naples, Italy) following the manufacturer's instructions as
previously reported [8]. Briefly, the SCCA ELISA kit is
based on a sandwich system whereby an HRP-conjugate
streptavidin secondary antibody is used to reveal the reac-
tion. A standard curve was also included as internal con-
trol, and samples were tested in duplicate to ensure
reproducible results.
Statistical analysis
Continuous non Gaussian distributed variables were
transformed into natural logarithms and described, after
back transformation, as means and 95% confidence inter-
vals. Comparisons between independent groups were per-
formed with Student's t test, and among more than two
groups, with a generalized linear model. Multiple com-
parisons were performed by means of Tukey grouping.
Pearson's coefficients were determined to evaluate corre-
lations between continuous variables. To evaluate the pre-
diction of S-SCCA as a function of tissue marker values, a
linear regression model was set up with the natural loga-
rithm of S-SCCA as the dependent variable and the natu-
ral logarithm of the tumoral and/or peritumoral SCCA
value as the independent variable. To evaluate the linear
relation of tumoral, peritumoral and serum SCCA as a
function of nodule size, a regression model was per-
formed only on single nodule observations.
To evaluate the diagnostic accuracy of serum SCCA a ROC
analysis was performed; cut-off value and related sensitiv-
ity, specificity, and Youden index were determined.
Qualitative variables were summarized as count and per-
centage. Comparisons between independent groups were
performed with chi-square test or Fisher's exact test when
appropriate.
All tests were considered statistically significant at a p-
value of < 0.05. Analyses were performed with SAS System
software for PC, version 9.1.
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